Adagio Medical shares surge 20.18% intraday after appointing two seasoned executives to accelerate commercialization of its ULTC ablation technology.

Adagio Medical (ADGM) surged 20.18% intraday following the announcement of two key executive appointments to accelerate commercialization of its Ultra-Low Temperature Cardiac Ablation (ULTC) technology. Marie-Claude Jacques, a seasoned sales leader with prior success scaling Baylis Medical’s revenue to $170 million, and Antwan Gipson, a manufacturing expert with a proven track record in scaling production for medical devices, were named Senior Vice Presidents. The hires signal strengthened readiness for the commercial launch of Adagio’s vCLAS Cryoablation System, currently in U.S. pivotal trials. With Jacques’ global sales expertise and Gipson’s cost-efficient manufacturing experience, the company emphasized these appointments as pivotal to achieving 2026 commercialization goals and long-term shareholder value. The news aligned with the stock’s sharp intraday rise, reflecting investor optimism about leadership’s ability to drive scalable growth.